iCellate can access the very rare
and continuously changing cancer cells
Cancer is a broad range of diseases that involves abnormal cell accumulation. Cancer originates from a primary tumor from which individual cells can spread through the lymphatic system or the blood stream to distant parts of the body and form metastases. Fatal therapy failure is almost always associated with metastases.
Circulating Tumor Cells (CTCs)
Cancer cells can migrate into the lymphatic and blood circulation system co-opting them as a transportation vehicle to ultimately metastasize to other parts of the body. Once in the blood, the vast majority of the circulating tumor cells actually die from natural causes, but a few survive, and a fateful few of those also attach at distant organs where they may exit the circulation and lodge in the distant organ and sooner or later may start to grow to form metastases.
Cancer diagnosis needs to properly capture and analyze those cancer cells that spread the disease, so that their properties can be determined, quickly and accurately. Those properties should then guide the clinical management of the disease.
iCellate’s CTC detection solution is label-free, meaning that it is biomarker independent. In contrast to some other methods that are biomarker dependent iCellate captures all CTCs, not just a subset.
Cancer therapy prediction is currently guided in part by analysis of biopsies from the primary tumor. We now know that metastases develop partially independently of the primary tumor and that biopsies therefore cannot be considered ideal bases for diagnosis. This may explain some initial therapy failures. With the information we now have available through ongoing research, we expect that the details of the properties of the collective of CTCs are closer to what we need to base our diagnoses on.